ABRAMSON JEREMY S ET AL: "Transcend NHL 001: Immunotherapy with the CD19-Directed CAR T-Cell Product JCAR017 Results in High Complete Response Rates in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma", BLOOD; 58TH ANNUAL MEETING AND EXPOSITION OF THE AMERICAN-SOCIETY-OF-HEMATOLOGY (ASH), SAN DIEGO, CA, USA , vol. 128, no. 22 2 December 2016 (2016-12-02), page 4192, XP009503775, ISSN: 0006-4971 Retrieved from the Internet: URL:http://www.bloodjournal.org/content/12 8/22/4192 [retrieved on 2018-02-27] (B1)

ARMIN GHOBADI: "Chimeric antigen receptor T cell therapy for non-Hodgkin lymphoma", CURRENT RESEARCH IN TRANSLATIONAL MEDICINE, vol. 66, no. 2, 11 April 2018 (2018-04-11) , pages 43-49, XP055531987, ISSN: 2452-3186, DOI: 10.1016/j.retram.2018.03.005 (B1)

J Abramson ET AL: "High Durable CR Rates in Relapsed/Refractory (R/R) Aggressive B-NHL Treated with the CD19-Directed CAR T Cell Product JCAR017 (TRANSCEND NHL 001): Defined Composition Allows for Dose-Finding and Definition of Pivotal Cohort", Blood, 1 January 2017 (2017-01-01), XP055668453, DOI: https://doi.org/10.1182/blood.V130.Suppl_1 .581.581 Retrieved from the Internet: URL:https://ashpublications.org/blood/arti cle/130/Supplement%201/581/115566/High-Dur able-CR-Rates-in-Relapsed-Refractory-R-R?s earchresult=1 [retrieved on 2020-02-13] (B1)

WO-A1-2019/109053 (B1)

R. LARSON ET AL: "Abstract 960: Defined cell composition and precise control over JCAR017 dose enables identification of relationships between chimeric antigen receptor T cell product attributes, pharmacokinetics, and clinical endpoints in NHL", 109TH ANNU MEET AM ASSOC CANCER RES (AACR), 1 July 2018 (2018-07-01), XP055668535, DOI: 10.1158/1538-7445.AM2018-960 (B1)

WO-A1-2015/157384 (B1)

J. Abramson ET AL: "Updated safety and long term clinical outcomes in TRANSCEND NHL 001, pivotal trial of lisocabtagene maraleucel (JCAR017) in R/R aggressive NHL", Journal of Clinical Oncology, 20 May 2018 (2018-05-20), XP055668523, Retrieved from the Internet: URL:https://ascopubs.org/doi/abs/10.1200/J CO.2018.36.15_suppl.7505 [retrieved on 2020-02-13] (B1)